chartexchange

MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

PR Newswire | Nov 13, 2026 8:31 AM EST

Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of Clinical Development for DA-1726 and Vanoglipel Full Data From the Phase 1 Parts 3A and 3B...

Read original article